Gain Therapeutics, Inc.
NASDAQ:GANXBiotechnology
+$0.06 today
- Market cap
- $50.33M
- Beta
- 0.16
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.50
Volume 4.26M
Average 0.64M
Returns on capital
Gain Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-108.6%
avg -18.8%
ROIC
-95.0%
avg 108.0%
ROA
-88.4%
avg -123.8%
Analysis
ROA is currently the strongest return metric at -88.4% versus its period average of -123.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Gene Mack | President, CEO, Director & Interim CFO | USD 664.32K | 52 | 200.00K | 0.47% |
Gianluca Fuggetta | Senior Vice President of Finance & Principal Financial Officer | USD 263.07K | 37 | 50.00K | 0.12% |
Khalid Islam | Chairman & Founder | USD 75K | 71 | 25.00K | 0.06% |
Joanne Taylor | Chief Scientific Officer | — | — | — | — |
Terenzio Ignoni | Chief Operating Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 18, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 15, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Gain Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about GANX's management, answered from reported figures.
Who manages GANX?
Gain Therapeutics, Inc. (GANX) lists 5 active executives. The top listed executive is Gianluca Fuggetta, Senior Vice President of Finance & Principal Financial Officer.
Are GANX insiders buying or selling?
Recent insider activity shows net buying of $33.82M.
Continue the stock analysis
Jump to another research area for this company.